Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf-/- mouse model.

about

YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics.Mouse models in the era of large human tumour sequencing studies

P2860

Q55634316-A6728001-C069-4F1A-8407-F3004C8D0C24 Q58776633-CE0CB7F6-9164-4D96-91E4-8A4F15E048B4

P2860

Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf-/- mouse model.

Item

http://www.wikidata.org/entity/Q41710165

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Resistance mechanisms to TP53- ...... reen in an Arf-/- mouse model.

@en

type

Item

label

Resistance mechanisms to TP53- ...... reen in an Arf-/- mouse model.

@en

prefLabel

Resistance mechanisms to TP53- ...... reen in an Arf-/- mouse model.

@en

P1476

Resistance mechanisms to TP53- ...... creen in an Arf-/- mouse model

@en

P2093

Agnieszka Gembarska

http://www.w3.org/2001/XMLSchema#string

Antoine de Weck

http://www.w3.org/2001/XMLSchema#string

Armelle Grevot

http://www.w3.org/2001/XMLSchema#string

Audrey Kauffmann

http://www.w3.org/2001/XMLSchema#string

Claire Estadieu

http://www.w3.org/2001/XMLSchema#string

Emeline Mandon

http://www.w3.org/2001/XMLSchema#string

Emilie A Chapeau

http://www.w3.org/2001/XMLSchema#string

Eric Y Durand

http://www.w3.org/2001/XMLSchema#string

Esther Sutter

http://www.w3.org/2001/XMLSchema#string

Francesco Hofmann

http://www.w3.org/2001/XMLSchema#string

P2860

A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4

Dissecting the genomic complexity underlying medulloblastoma

Cancer Evolution and the Limits of Predictability in Precision Cancer Medicine

Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors

Discovery of a novel class of highly potent inhibitors of the p53-MDM2 interaction by structure-based design starting from a conformational argument

Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.

Divorcing ARF and p53: an unsettled case

Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas

Significant Differences in the Development of Acquired Resistance to the MDM2 Inhibitor SAR405838 between In Vitro and In Vivo Drug Treatment

Signatures of mutational processes in human cancer

P304

3151-3156

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1620262114

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

114

http://www.w3.org/2001/XMLSchema#string

P50

Sebastien Jeay

P577

2017-03-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28265066

http://www.w3.org/2001/XMLSchema#string

P932

5373361

http://www.w3.org/2001/XMLSchema#string

Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf-/- mouse model.

about

P2860

P2860

Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf-/- mouse model.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932